|Articles|June 12, 2020
Survival benefit in advanced or metastatic breast cancer with visceral metastases
Author(s)Lindsey Carr, Editor
Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.
Advertisement
The findings are from a subgroup analysis of the phase 3 MONALESSA-3 and MONALEESA-7 trials and were presented during the ASCO20 Virtual Scientific Program.
Learn more and read the full article from
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
GLP-1 RAs linked to broad menstrual adverse event signals in reproductive-aged patients
2
Biomarker testing for preeclampsia with Lisa A. Bukovac, DO, FACOG
3
Q+A: Connor Frey, MD, on GLP-1 RAs and menstrual adverse event signals
4
HIV screening, PrEP counseling get stronger ACOG recommendation
5